N. Girard , J. Bonastre , G. Spurrier-Bernard , H. Lemasson , M. Chartier , V. Moreau-Mallet , S. Micheliza , N. Texier , S. Hervy , M. Coin-Bavarot , C. Robert
{"title":"晚期或转移性非小细胞肺癌(NSCLC)或黑色素瘤患者对免疫检查点抑制剂(ICI-DR)持久反应的生活质量(QoL)和护理途径:QUALICI研究","authors":"N. Girard , J. Bonastre , G. Spurrier-Bernard , H. Lemasson , M. Chartier , V. Moreau-Mallet , S. Micheliza , N. Texier , S. Hervy , M. Coin-Bavarot , C. Robert","doi":"10.1016/j.iotech.2024.100838","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":73352,"journal":{"name":"Immuno-oncology technology","volume":"24 ","pages":"Article 100838"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"95P Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study\",\"authors\":\"N. Girard , J. Bonastre , G. Spurrier-Bernard , H. Lemasson , M. Chartier , V. Moreau-Mallet , S. Micheliza , N. Texier , S. Hervy , M. Coin-Bavarot , C. Robert\",\"doi\":\"10.1016/j.iotech.2024.100838\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":73352,\"journal\":{\"name\":\"Immuno-oncology technology\",\"volume\":\"24 \",\"pages\":\"Article 100838\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-12-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Immuno-oncology technology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590018824001357\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Immuno-oncology technology","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590018824001357","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
95P Quality of life (QoL) and care pathway in patients with durable response to immune checkpoint inhibitors (ICI-DR) for advanced or metastatic non-small cell lung cancer (NSCLC) or melanoma: QUALICI study